- Home
- PEGA vs LNTH Comparison
PEGA vs LNTH Comparison
Compare PEGA & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PEGA | LNTH |
|---|---|---|
| Founded | 1983 | 1956 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 4.4B |
| IPO Year | 1996 | 2015 |
Fundamental Metrics
Financial Performance| Metric | PEGA | LNTH |
|---|---|---|
| Price | $60.00 | $69.66 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 6 |
| Target Price | $66.69 | ★ $78.00 |
| AVG Volume (30 Days) | 1.1M | ★ 1.1M |
| Earning Date | 02-11-2026 | 02-25-2026 |
| Dividend Yield | ★ 0.20% | N/A |
| EPS Growth | ★ 116.89 | N/A |
| EPS | 1.46 | ★ 2.39 |
| Revenue | ★ $1,732,325,000.00 | $1,525,933,000.00 |
| Revenue This Year | $18.36 | $0.01 |
| Revenue Next Year | $7.17 | $0.52 |
| P/E Ratio | $40.14 | ★ $28.83 |
| Revenue Growth | ★ 17.00 | 1.95 |
| 52 Week Low | $29.84 | $47.25 |
| 52 Week High | $68.10 | $111.29 |
Technical Indicators
Market Signals| Indicator | PEGA | LNTH |
|---|---|---|
| Relative Strength Index (RSI) | 51.66 | 71.09 |
| Support Level | $55.33 | $66.36 |
| Resistance Level | $62.89 | $67.45 |
| Average True Range (ATR) | 2.06 | 1.69 |
| MACD | -0.31 | -0.01 |
| Stochastic Oscillator | 58.83 | 93.81 |
Price Performance
Historical ComparisonAbout PEGA Pegasystems Inc.
Founded in 1983, Pegasystems provides a suite of solutions for customer engagement and business process management. The company's key offering is the Pega Infinity platform, which combines business process management with customer relationship management applications. The company focuses on enterprise-size customers in the financial, insurance, and healthcare industries.
About LNTH Lantheus Holdings Inc.
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.